PUF Ventures Inc. (CSE:PUF, Frankfurt:PU3, OTCPK:PUFXF) (“PUF” or the “Company”), an advanced Access to Cannabis for Medical Purposes Regulations (“ACMPR”) license applicant, is pleased to announce that the Company has appointed Dr. Peter Tolias to its Advisory Board. The Advisory Board oversees all areas of research and development related to PUF’s medical cannabis initiatives.
“I am delighted to welcome Dr. Tolias to our Advisory Board,” said Derek Ivany, President and CEO of PUF Ventures Inc. “Dr. Tolias is a talented and strategically-focused life sciences professor, administrator and industry executive. With over three decades of academic and professional accomplishments, Peter brings to PUF senior academic management experience leading research centers, institutes and academic departments, plus senior corporate management experience at both small and fortune 100 companies. I look forward to working closely with Dr. Tolias, and the recently appointed Dr. Khursigara, to develop proprietary genetics and cannabis strains, and initiate research and development to unlock the secrets of medical cannabis.”
Dr. Peter Tolias is currently Professor and Chair of the Department of Chemistry and Chemical Biology and Director of the Center for Healthcare Innovation at the Stevens Institute of Technology. Dr. Tolias received his Ph.D. from McGill University and served as an Associate in the Department of Cellular & Developmental Biology at Harvard University. He is the founder of several biotechnology companies plus a capital sourcing and consulting firm specializing in the biotechnology sector. Dr. Tolias’ academic and corporate expertise includes molecular, cellular and developmental biology, microbiology, immunology, genetics, genomics, proteomics and tissue engineering.
About PUF Ventures Inc.
PUF Ventures Inc. is a growth oriented and diversified company focused on the international cannabis industry. It has ownership in several cannabis companies: AAA Heidelberg, Solaris Nutraceuticals Pty Ltd., and Natures Hemp Corp., and is actively pursuing other opportunities within the industry. PUF has an option to purchase 100% of AAA Heidelberg Inc., an advanced applicant for an ACMPR license. Solaris Nutraceuticals is building the largest medical cannabis greenhouse in the Southern Hemisphere. For more information please visit: www.puf.ca.
ON BEHALF OF THE BOARD OF DIRECTORS
President & CEO
No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.
Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.
Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to announce the initial order of Nextleaf’s Rapid Emulsion Technology by OILS™ (“Rapid”) THC and CBD to cannabis-infused beverage manufacturer, BevCanna Enterprises Inc. (“BevCanna”).
With this initial order, Nextleaf’s Rapid concentrate becomes one of BevCanna’s preferred ingredients, available for use in both their brands and their partner brands. Rapid is Nextleaf’s patent pending delivery technology.
Both locations expand access to the state’s widest-ranging inventory of medical cannabis products for Central Florida patients
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of two brand-new Central Florida dispensaries. The new Clearwater and Tampa locations mark the Company’s 81 st and 82 nd nationwide, respectively, widening patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.
Philip Young, CEO and Director of Lobe, stated, “We are honored to welcome Bart to our Advisory Board. His first-hand experience on and off the field are tremendously valuable as we continue our research involving mild traumatic brain injuries and PTSD. These issues are prevalent in contact sports and we believe that athletes will play a prominent role in the continued acceptance of psychedelic medicines as legitimate treatment. We look forward to working with Bart as we seek to forge long-term strategic relationships.”